Tirzepatide, marketed under the name Mounjaro, is positioned as a novel therapeutic option for obesity management, demonstrating significant weight loss in clinical trials (up to 21%). This multicenter retrospective observational study in the Netherlands aims to evaluate real-world effectiveness and dosing patterns, which could provide critical insights into its practical application and market acceptance. The study's findings may influence prescribing habits and reimbursement strategies, especially as obesity treatment continues to gain attention in healthcare systems. Given the increasing prevalence of obesity and associated comorbidities, Tirzepatide has the potential to capture a substantial share of the obesity treatment market, particularly if it demonstrates favorable outcomes in real-world settings compared to existing therapies.